vantage point villar
| | | | |

[Vantage Point] Villar Land: Follow the P1.3-trillion paper trail

(Second of two parts. Part 1: The Villar Land scandal now has a gatekeeper problem)

Follow the sequence: related-party acquisitions, a massive revaluation, almost P1 trillion in reported profit and an extraordinary market valuation—followed eventually by an accounting reversal. The P1.3-trillion paper trail shows why the Villar Land saga is no longer just about one company, but about the integrity of the Philippine capital market.

The Villar Land saga becomes clearer when we stop looking at the trillion-peso valuation as one spectacular accounting number and follow the sequence that produced it: related-party acquisitions, revaluation, financial-statement recognition, and an extraordinary stock-market valuation.

How did so much paper wealth travel so far before the accounting was reversed?

In my column yesterday, I examined the uncomfortable question raised by documents surrounding Villar Land Holdings Corp.: where were the financial gatekeepers while one of the most extraordinary accounting transformations in Philippine corporate history was unfolding? 

But there is another way to examine this story. Follow the P1.3 trillion through the corporate structure, accounting entries, financial statements, and ultimately into the market narrative that helped make the market believe that Villar Land was one of the Philippines’ most valuable listed companies.

The starting point was not P1.3 trillion. It was land. In September 2024, Villar Land—then Golden MV Holdings—acquired Althorp Land Holdings Inc., Chalgrove Properties Inc., and Los Valores Corp. 

Together, the three companies held about 366 hectares inside Villar City, the sprawling 3,500-hectare development south of Metro Manila. Documents reviewed by Vantage Point identify the three companies as related parties under the Fine Properties umbrella. 


[Vantage Point] Villar Land: Follow the P1.3-trillion paper trail

Nothing wrong with a related-party transaction. Philippine conglomerates routinely transfer assets among companies controlled by the same families or corporate groups. But these transactions deserve heightened scrutiny because buyer and seller are not strangers bargaining independently across a table. 

What happened after these properties entered Villar Land makes that scrutiny considerably more important.

Villar Land recorded the properties as investment properties and adopted fair-value accounting. By March 28, 2025, the consequences were astonishing. Investment properties had ballooned to P1.340 trillion from P738 million the previous year.

Fair-value gains reached P1.331 trillion. Net profit exploded from P1.461 billion to P999.720 billion, total assets from P28.64 billion to P1.367 trillion, and stockholders’ equity from P14.614 billion to P1.012 trillion. 

But if we dig in into this apparent financial miracle, the actual business was moving backward. Revenue fell 25% from P4.759 billion to P3.577 billion, while operating profit dropped 29% from P1.712 billion to P1.216 billion. 

The operating company became weaker while its accounting reflected a company becoming unimaginably richer. There was no trillion-peso influx of cash, property sales, or rental income. An accounting measurement virtually performed a cosmetic surgery that radically transformed the company’s financial appearance.

This is where the sequence becomes important. What I uncovered describes a potentially dangerous loop: acquire property, revalue it, book gains, inflate share prices, justify further acquisitions, then repeat. 

The documents I have in possession establish the acquisition, revaluation, and recognition of enormous accounting gains. They also establish that Villar Land subsequently carried an extraordinary stock-market valuation

They do not, standing alone, prove that the revaluation caused the share price to rise or that management adopted the accounting treatment to influence the stock. Sequence is not necessarily causation, and causation is not necessarily intent.

But investors are entitled to examine that sequence. Related-party assets entered the listed company, were subjected to fair-value accounting, and the resulting gains transformed Villar Land‘s earnings, assets, and equity. 

Those numbers entered the public domain while its shares traded at prices implying a corporate valuation vastly removed from the scale of its underlying business.

Villar Land shares ultimately traded around P2,300. With roughly 644 million shares outstanding, that implied a market capitalization approaching P1.5 trillion. 

A company generating ordinary operating profit of about P1.2 billion had acquired a valuation comparable with some of the country’s largest conglomerates. That was what made me suspicious when I first examined Villar Land in May 2025. The economics simply did not fit the market capitalization.

Accounting wealth

Then something extraordinary happened again: the accounting was reversed. Material reproducing the external auditor’s later report says the originally issued separate financial statements had changed the accounting policy for investment properties from the cost model to the fair-value model

After further discussions between management and the external auditor, management decided to retain the cost model instead, reversing the earlier accounting, and revising the financial statements. 

The land did not disappear, nor did Villar City, or the 366 hectares. What disappeared was the accounting treatment that had allowed enormous unrealized appreciation to flow through the financial statements. 

That is why investors must distinguish economic wealth from accounting wealth. One ultimately requires somebody to pay for the asset; the other can arise from assumptions embedded in a valuation model.

The related-party dimension makes this more deserving of scrutiny. When unrelated parties negotiate a property sale, the transaction price provides evidence of what independent participants believe the property is worth. 

When assets move among related companies, the transaction may be legitimate, but investors have greater reason to examine whether the transfer price represents genuine independent price discovery. 

If those assets are subsequently marked dramatically higher, shareholders deserve to know how the value was established and how aggressively the assumptions were challenged. At P1.331 trillion, the burden of credibility becomes extraordinary.

I could argue, based on the documents I have, that the disclosures and audit opinion made the valuation appear reliable and helped sustain Villar Land’s stock price. 

I am not prepared to make that causal claim from these documents alone. Villar Land was unusually illiquid, and market capitalization merely multiplies the last traded price by outstanding shares; it does not mean P1.5 trillion actually changed hands.

But that may make the market-integrity issue more troubling. In a thinly traded stock, relatively limited trading can establish a quoted price applied across hundreds of millions of shares, creating enormous paper wealth.

That is why the subsequent allegations made by the Securities and Exchange Commission (SEC) about artificial demand involving related entities are crucial. Those allegations remain subject to due process, but they raise the possibility that financial disclosure and trading activity interacted in ways that distorted genuine price discovery.

Must Read

SEC chief Francis Lim to Villars: No family is too powerful to sue


SEC chief Francis Lim to Villars: No family is too powerful to sue

Put the sequence together: related-party properties entered Villar Land, were revalued; generated enormous paper gains, transformed profit, assets, and equity; and reached investors while the company commanded an extraordinary market valuation. The accounting was subsequently reversed. Each step may have an explanation, and the documents do not establish that the sequence was deliberately engineered. Together, however, they demand scrutiny.

The gatekeepers

Capital markets function because investors trust a chain of gatekeepers—corporate management, property appraisers, audit committees, external auditors, the Philippine Stock Exchange (PSE), and the Securities and Exchange Commission (SEC). 

Ordinary investors stand at the very end of that regulatory pipeline: they cannot directly inspect boardrooms, analyze company files, or review audit working papers. 

In Villar Land’s case, a massive P1.3 trillion in unearned paper gains slipped past nearly every regulatory checkpoint before the accounting behind them was reversed. The real issue is no longer simply how Villar Land produced such an astronomical figure. 

It is understanding how the company’s trillion-peso valuation managed to sail through so many institutional gates before someone finally stepped in to block it. – Rappler.com

Below are some Vantage Point pieces you might have missed:

Click here for other Vantage Point articles

Similar Posts

  • | | |

    Shein posts $99m loss ahead of Hong Kong IPO

    Online fashion retailer Shein has reported a $99 million loss for the first quarter of 2026, highlighting the growing impact of higher import costs, weaker US sales and increased regulatory pressure. The company had recorded a $395 million profit during the same period a year earlier. Its latest financial disclosure comes as Shein prepares for a planned listing in Hong Kong. The company has not yet revealed the size of the initial public offering, expected share price, listing date or the amount it hopes to raise. However, the filing provides investors with a clearer picture of the challenges facing the fast-fashion giant ahead of its potential market debut. A major factor behind the weaker performance is the removal of a US duty exemption for low-value packages. The previous system allowed goods worth less than $800 to enter the country without import duties. Shein said the change has negatively affected its US sales and overall growth while increasing operating expenses. Products of Chinese origin sold through the company and shipped to the US are now subject to taxes ranging from 10% to 87.5%, according to the filing. The company said it is considering several measures to manage the higher costs, including raising prices for American customers. Shein’s US revenue fell 14.3% to $2.04 billion in the first quarter, compared with $2.38 billion a year earlier. The US remains one of its most important markets, although its contribution to total revenue has declined. The company is also facing additional pressure in Europe. The European Union has introduced a €3 charge on low-value e-commerce imports, a move aimed at addressing concerns over competition from low-cost overseas sellers. Shein warned that the European market could experience an impact similar to, or greater than, the one seen in the US following the removal of the duty exemption. The retailer’s financial performance had already weakened in 2025. Its annual revenue increased by 8% to $41.85 billion, but net income dropped nearly 39% to $2.06 billion. Growth also slowed significantly compared with the previous year. Part of the latest quarterly loss was linked to a $328 million accounting charge related to the changing value of convertible preferred shares held by investors. Shein has also faced growing scrutiny over labour practices, environmental concerns and the impact of its business model. The company has defended its policies and said it maintains strict standards against labour abuses within its supply chain. Shein received approval from Chinese regulators for its Hong Kong listing in July, clearing an important hurdle after earlier efforts to pursue listings in New York and London did not materialise.

  • | |

    4 cash-filled bags: Bank exec’s testimony supports Madriaga’s story on confi funds

    A bank official confirms seeing two Office of the Vice President officials put P125 million in cash inside four bags, complementing a claim made by Sara Duterte’s alleged bagman Ramil Madriaga on what happened on December 20, 2022

  • | | |

    Ministers seek PM’s approval for prices of 52 vi…

    ISLAMABAD: The federal health ministry has sought an urgent meeting with Prime Minister Shehbaz Sharif to obtain approval for the pricing of 52 newly registered life-saving medicines. Health Minister Syed Mustafa Kamal and Finance Minister Senator Muhammad Aurangzeb are expected to attend the meeting along with Federal Health Secretary Muhammad Aslam Ghauri and Drug Regulatory Authority of Pakistan (DRAP) Chief Executive Officer Dr Obaidullah. Officials said the health ministry has contacted the prime minister’s adviser, Tauqeer Shah, requesting an early appointment for the delegation. The Cabinet Committee on Drug Pricing had already approved prices for the 52 medicines during its meeting on July 24. However, the medicines cannot be legally marketed in Pakistan until the federal cabinet gives its final approval. After cabinet approval, DRAP will be able to issue notifications fixing the maximum retail prices of the medicines, allowing pharmaceutical companies to formally launch the products in the regulated market. Health ministry officials said the proposed meeting with the prime minister is aimed at obtaining his support for placing the pricing decision before the federal cabinet at the earliest. The delegation is also expected to raise the issue of hardship cases involving several essential medicines. Manufacturers and importers of these medicines have requested price adjustments, arguing that continued production or imports at the existing prices have become increasingly difficult. A senior health ministry official said the government was concerned because several registered medicines remained unavailable in the regulated market despite their prices having been approved by the drug pricing committee. The official said the delegation would brief the prime minister on the situation and seek immediate action to prevent further shortages. Among the medicines facing supply pressure are essential products such as influenza vaccines and morphine used in cancer treatment, along with other drugs whose manufacturers have reported difficulties in maintaining supplies at existing prices. The Cabinet Committee on Drug Pricing, chaired by Finance Minister Muhammad Aurangzeb, approved the 52 pricing cases after reviewing recommendations submitted by DRAP’s Drug Pricing Committee and Policy Board. All 52 cases forwarded by the Drug Pricing Committee and endorsed by the DRAP Policy Board were approved by the cabinet committee. However, the committee’s decision is not the final step in the process. The federal cabinet must endorse the recommendations before DRAP can officially notify the maximum retail prices. The medicines covered by the proposed pricing decision are used to treat a range of serious and chronic conditions. They include medicines for cancer, diabetes, haemophilia, Parkinson’s disease, autoimmune disorders, blood-clotting conditions and severe infections. Some are also used in intensive-care units and emergency treatment. Officials believe timely approval could help bring the newly registered medicines into the regulated market and improve availability for patients requiring specialised treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *